(Total Views: 77)
Posted On: 07/22/2025 12:28:45 PM
Post# of 29851
Took a position in $PSTV @.3969 a share with a target of .65
Chart looks like its setting up for a move.
Massive Analyst Upside
Analysts from HC Wainwright, Ascendiant Capital, and D. Boral Capital have targets ranging from $3 to $21, with a consensus of $10.831.
Even the lowest target ($3) represents a 650%+ gain from current levels.
2. Low Float + High Volatility
With only ~12M shares in the float, PSTV can move quickly on volume or news.
Historically, it has shown explosive moves on trial updates or biotech sector momentum.
3. Technical Setup
Currently consolidating just above support ($0.35–$0.38 zone).
MACD is flattening, suggesting a potential bullish crossover.
RSI is neutral, indicating no overbought pressure.
4. Fundamental Catalyst
PSTV is advancing targeted radiotherapeutics for brain/spinal tumors.
Phase 2 trial data for Rhenium-186 is expected soon, which could be a major catalyst.
Chart looks like its setting up for a move.
Massive Analyst Upside
Analysts from HC Wainwright, Ascendiant Capital, and D. Boral Capital have targets ranging from $3 to $21, with a consensus of $10.831.
Even the lowest target ($3) represents a 650%+ gain from current levels.
2. Low Float + High Volatility
With only ~12M shares in the float, PSTV can move quickly on volume or news.
Historically, it has shown explosive moves on trial updates or biotech sector momentum.
3. Technical Setup
Currently consolidating just above support ($0.35–$0.38 zone).
MACD is flattening, suggesting a potential bullish crossover.
RSI is neutral, indicating no overbought pressure.
4. Fundamental Catalyst
PSTV is advancing targeted radiotherapeutics for brain/spinal tumors.
Phase 2 trial data for Rhenium-186 is expected soon, which could be a major catalyst.
(0)
(0)
